| 1 |
34197574 | Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis B Virus-Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort. | 2022 Mar 23 |
1 |
| 2 |
33259998 | Viral Hepatitis in pregnancy. | 2021 Jan |
1 |
| 3 |
33587439 | Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine. | 2021 Apr 1 |
1 |
| 4 |
33614029 | Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. | 2021 Jan-Dec |
1 |
| 5 |
33633036 | Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial. | 2021 Jun 1 |
2 |
| 6 |
33663172 | [Epidemiology and influencing factors of human immunodeficiency virus and hepatitis B virus co-infected patients in Beijing]. | 2021 Mar 1 |
1 |
| 7 |
32041580 | Trabecular bone scores in young HIV-infected men: a matched case-control study. | 2020 Feb 10 |
1 |
| 8 |
32180249 | Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis. | 2020 Sep |
1 |
| 9 |
32596332 | The Risk of Acute Kidney Injury in Hepatitis B Virus-Related Acute on Chronic Liver Failure with Tenofovir Treatment. | 2020 |
1 |
| 10 |
30259350 | Evaluation of drug resistance mutations in patients with chronic hepatitis B. | 2019 Mar |
1 |
| 11 |
30985556 | Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. | 2019 Aug 1 |
1 |
| 12 |
31114265 | Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B. | 2019 |
1 |
| 13 |
31142283 | The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. | 2019 May 29 |
1 |
| 14 |
31147594 | Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection. | 2019 May 30 |
2 |
| 15 |
31258661 | Efficacy of long-term treatment with tenofovir in Chinese nucleos(t)ide-naïve chronic hepatitis B patients regardless of baseline viral load. | 2019 Jul |
1 |
| 16 |
29433097 | Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs. | 2018 Apr 15 |
2 |
| 17 |
29602711 | Tenofovir disoproxil fumarate co-administered with lopinavir/ritonavir is strongly associated with tubular damage and chronic kidney disease. | 2018 Jul |
1 |
| 18 |
29746295 | The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? | 2018 Jul 31 |
1 |
| 19 |
30047286 | Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor. | 2018 Oct |
1 |
| 20 |
30075765 | Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study. | 2018 Aug 3 |
2 |
| 21 |
27553871 | Renal outcomes after up to 8 years of tenofovir exposure in HIV-HBV-coinfected patients. | 2017 |
1 |
| 22 |
27809359 | Renal function in HIV/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life setting. | 2017 Feb |
1 |
| 23 |
27898591 | Tenofovir exposure in utero and linear growth in HIV-exposed, uninfected infants. | 2017 Jan 2 |
1 |
| 24 |
27903949 | Possible Drug-Herb Interaction between Herbal Supplement Containing Horsetail ( Equisetum arvense) and Antiretroviral Drugs. | 2017 Jan/Feb |
1 |
| 25 |
28076335 | Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate. | 2017 |
2 |
| 26 |
28288232 | [Tenofovir-associated Fanconi`s syndrome and rickets in a HIV infected girl]. | 2017 Feb |
1 |
| 27 |
28392234 | Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. | 2017 Aug |
1 |
| 28 |
28583112 | Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients. | 2017 Jun 5 |
1 |
| 29 |
28638661 | Efficacy and Tolerability of Tenofovir Disoproxil Fumarate Based Regimen as Compared to Zidovudine Based Regimens: A Systematic Review and Meta-Analysis. | 2017 |
2 |
| 30 |
28902074 | Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. | 2017 Dec 15 |
1 |
| 31 |
29216208 | Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study. | 2017 |
1 |
| 32 |
29270324 | Early Onset of Tenofovir-Related Fanconi Syndrome in a Child with Acute Hepatitis B: A Case Report and Systematic Review of Literature. | 2017 |
1 |
| 33 |
26689970 | Brief Report: HIV-1 Evolution in Breakthrough Infections in a Human Trial of Oral Pre-exposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate. | 2016 Jun 1 |
1 |
| 34 |
26892863 | Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. | 2016 Mar |
1 |
| 35 |
26988401 | Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients. | 2016 Jun |
1 |
| 36 |
27196332 | An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. | 2016 |
1 |
| 37 |
27560968 | Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific. | 2016 |
1 |
| 38 |
27806064 | Antiretroviral Drug Activity in Macaques Infected during Pre-Exposure Prophylaxis Has a Transient Effect on Cell-Associated SHIV DNA Reservoirs. | 2016 |
1 |
| 39 |
27809711 | Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection. | 2016 Nov |
1 |
| 40 |
25070158 | Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1. | 2015 Feb |
1 |
| 41 |
25782332 | Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings? | 2015 Jul |
1 |
| 42 |
25856383 | Renal Function in Chronic Hepatitis B Patients Treated With Tenofovir Disoproxil Fumarate or Entecavir Monotherapy: A Matched Case-Cohort Study. | 2015 Nov-Dec |
1 |
| 43 |
25956353 | Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination. | 2015 Jul 1 |
1 |
| 44 |
25973716 | Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir. | 2015 Oct |
1 |
| 45 |
26021773 | Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients. | 2015 May-Jun |
1 |
| 46 |
26045359 | Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF. | 2015 Aug |
1 |
| 47 |
26121361 | Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients. | 2015 |
1 |
| 48 |
26286337 | Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF. | 2015 Oct |
1 |
| 49 |
26347243 | A 68-year old male presenting with rhabdomyolysis-associated acute kidney injury following concomitant use of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and pravastatin/fenofibrate: a case report. | 2015 Sep 8 |
1 |
| 50 |
26690199 | Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study. | 2015 Dec 7 |
1 |